A Polyphenol-Rich Extract From Muscadine Grapes Inhibits Triple-Negative Breast Tumor Growth.
cyclin D1
muscadine grape
polyphenols
proliferation
triple-negative breast cancer
Journal
Integrative cancer therapies
ISSN: 1552-695X
Titre abrégé: Integr Cancer Ther
Pays: United States
ID NLM: 101128834
Informations de publication
Date de publication:
Historique:
entrez:
25
6
2020
pubmed:
25
6
2020
medline:
31
7
2021
Statut:
ppublish
Résumé
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that tends to affect young women and has a high propensity to metastasize. No targeted treatments are available for this type of breast cancer due to a lack of estrogen or progesterone receptors or overexpression of human epidermal growth factor receptor type 2 overexpression. Currently, patients have no therapeutic options once standard of care is complete, indicating a need for safe and effective therapies to slow or prevent the progression of TNBC to metastatic disease. Studies showed that isolated polyphenols or polyphenol-rich muscadine grape extracts polyphenols inhibit the proliferation of various cancer cells including breast cancer. A proprietary muscadine grape extract (MGE) was administered to nude mice with human MDA-MB-231 TNBC atumors for 4 weeks to determine the effect of the extract on tumor growth. MGE decreased tumor volume in association with a reduction in the proliferative markers Ki67 and cyclin D1. To determine the molecular mechanisms for the MGE-induced reduction in tumor growth, mouse 4T1, MDA-MB-231, or human BT-549 TNBC cells were treated with MGE, and various signaling pathways were investigated. MGE reduced c-Met, differentially abrogated ERK/MAPK and AKT signaling, and decreased a downstream targets of ERK/MAPK and AKT pathways, cyclin D1. Cyclin D1 reduction was associated with retinoblastoma activation and cell cycle arrest in MDA-MB-231 TNBC cells. MGE-regulated molecular signaling pathways were functionally associated with a dose-dependent reduction in cell proliferation. The pluripotency of MGE and high index of safety and tolerability suggest that the extract may serve as a therapeutic to reduce TNBC progression to metastatic disease.
Identifiants
pubmed: 32578460
doi: 10.1177/1534735420917444
pmc: PMC7315667
doi:
Substances chimiques
Plant Extracts
0
Polyphenols
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1534735420917444Subventions
Organisme : NCI NIH HHS
ID : P30 CA012197
Pays : United States
Références
Biochim Biophys Acta. 2011 Nov;1813(11):1978-86
pubmed: 21440011
Ther Adv Med Oncol. 2011 Nov;3(1 Suppl):S7-S19
pubmed: 22128289
Cancer Treat Rev. 2018 Jan;62:110-122
pubmed: 29202431
Oncogene. 2008 Feb 14;27(8):1106-13
pubmed: 17724476
Prostate. 2015 Oct;75(14):1518-25
pubmed: 26012728
Discov Med. 2014 May;17(95):275-83
pubmed: 24882719
Breast Cancer Res. 2015 Apr 08;17:52
pubmed: 25887320
Cancer. 2010 Jun 1;116(11):2549-59
pubmed: 20336785
Cell Signal. 2008 Apr;20(4):581-9
pubmed: 18023328
Carcinogenesis. 2014 Oct;35(10):2321-30
pubmed: 25023990
Prim Care Companion CNS Disord. 2011;13(2):
pubmed: 21977340
Mol Cancer. 2018 Feb 19;17(1):34
pubmed: 29455658
Trends Biochem Sci. 2011 Jun;36(6):320-8
pubmed: 21531565
Front Oncol. 2012 Aug 07;2:88
pubmed: 22891162
J Cell Sci. 2008 Dec 1;121(Pt 23):3853-7
pubmed: 19020303
Oncol Rep. 2015 Jul;34(1):375-81
pubmed: 25997470
Nat Rev Cancer. 2002 Jul;2(7):489-501
pubmed: 12094235
Ther Adv Med Oncol. 2017 Jul;9(7):493-511
pubmed: 28717401
Mol Cancer. 2018 Jul 25;17(1):104
pubmed: 30045773
Oncogene. 2002 Aug 15;21(36):5515-28
pubmed: 12165850
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Nat Rev Clin Oncol. 2016 Nov;13(11):674-690
pubmed: 27184417
Mod Pathol. 2011 Feb;24(2):157-67
pubmed: 21076464
Breast Cancer (Auckl). 2015 Sep 01;9(Suppl 1):23-34
pubmed: 26380552
Nat Rev Clin Oncol. 2012 May 08;9(6):314-26
pubmed: 22566105
J Chromatogr A. 2012 Jun 1;1240:96-103
pubmed: 22520637
Mol Cell Biol. 2002 Nov;22(22):7842-52
pubmed: 12391153
J Agric Food Chem. 2006 Jul 26;54(15):5336-43
pubmed: 16848514
Mol Cancer. 2007 Apr 02;6:24
pubmed: 17407548
Oncotarget. 2016 Aug 30;7(35):56767-56780
pubmed: 27462923
Heliyon. 2019 Jan 16;5(1):e01128
pubmed: 30705983
PLoS One. 2013 Nov 12;8(11):e78641
pubmed: 24265703
Breast Cancer Res Treat. 2009 May;115(2):423-8
pubmed: 18543098
Food Nutr Res. 2017 Dec 10;61(1):1412795
pubmed: 29249924
Clin Breast Cancer. 2009 Jun;9 Suppl 2:S73-81
pubmed: 19596646
J Cancer. 2011;2:324-8
pubmed: 21716849
Oncol Rep. 2011 Jul;26(1):177-84
pubmed: 21503582
Oncogene. 2001 Apr 30;20(19):2390-400
pubmed: 11402335
Genes Dev. 2002 Jun 1;16(11):1356-70
pubmed: 12050114
Anal Biochem. 2014 Dec 15;467:1-3
pubmed: 25193447
Cancer Res. 2007 Sep 1;67(17):8396-405
pubmed: 17804756
Int J Cancer. 1994 May 1;57(3):353-61
pubmed: 8168995
Cold Spring Harb Perspect Biol. 2015 Dec 01;7(12):
pubmed: 26626938